Stoke Therapeutics Inc Stock
Stoke Therapeutics Inc Stock
We can see a decrease in the price for Stoke Therapeutics Inc. Compared to yesterday it has lost -€0.400 (-1.410%).
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Stoke Therapeutics Inc.
With a target price of 33 € there is a slightly positive potential of 13.09% for Stoke Therapeutics Inc compared to the current price of 29.18 €.
So far the community has only identified positive things for Stoke Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | -1.410% | 4.964% | -12.108% | 430.545% | 7.279% | - | - |
| Personalis Inc | -3.920% | -8.905% | -24.894% | 90.963% | -23.501% | 109.593% | -73.354% |
| Immuron | -0.790% | -1.563% | -10.000% | -50.394% | -6.667% | -62.941% | -87.037% |
Comments
Stoke Therapeutics (STOK) had its price target raised by Canaccord Genuity Group Inc. from $36.00 to $60.00. They now have a "buy" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat